Click here for important disclosures about sponsor fees.ģ) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. She or members of her household are paid by the following companies mentioned in this article: None.Ģ) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. She or members of her household own securities of the following companies mentioned in the article: None.
Tyme stocktwits free#
Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter.ġ) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. ROTH has a Buy rating and a $23 per share target price on Syros, the current share price of which is around $0.77. However, the company has decided to postpone all subsequent trials, except for the pivotal Phase 3 Tamibarotene in higher-risk myelodysplastic syndromes, until it has secured additional capital.
Tyme stocktwits trial#
The third expected data readout will be from the Phase 1 trial of SY-5609 plus chemotherapy for relapsed or refractory metastatic prostate cancer.Īs for its balance sheet, Syros ended Q1/22 with $112.9 million in cash, cash equivalents, and marketable securities, enough to support operations into Q2/23, management noted. The second batch of results, pharmacokinetic and safety data, is slated for release from the Phase 3 dose confirmation study of SY-2101 in acute promyelocytic leukemia. "A key focus for us in the upcoming data readout will be 1) is the three-drug regimen safe relative to the standard of care and 2) is the complete response rate or complete response rate with incomplete blood recovery supportive of moving this program into a potentially pivotal randomized, placebo-controlled study," Jallah wrote. The current standard of care is venetoclax plus azacitidine. One set will be safety lead-in data from the Phase 2 study of Tamibarotene plus venetoclax plus azacitidine in acute myeloid leukemia. Trial results are expected in H2/22 for all three pipeline drugs. SY-5609, an oral selective CDK7 inhibitor, is the third being tested in colorectal and metastatic prostate cancers. The company's second most advanced therapeutic candidate is SY-2101, an oral arsenic trioxide being evaluated in newly diagnosed acute promyelocytic leukemia. Its lead drug candidate is Tamibarotene, a retinoic acid receptor alpha agonist, which Syros is pursuing in newly diagnosed higher risk myelodysplastic syndromes and newly diagnosed unfit acute myeloid leukemia. The pharma company is advancing a pipeline of small molecule drugs that control the expression of genes to treat cancer and genetic diseases. "The three upcoming catalysts in 2022 could bolster Syros' cash position and provide breathing room necessary to see their programs to fruition," Jallah wrote.
(SYRS:NASDAQ) is on track for a trio of potential de-risking catalysts, in the form of data readouts, to occur in H2/22, reported ROTH Capital Partners analyst Zegbeh Jallah in a March 17 research note.
0 kommentar(er)
